Advertisement

Molecular and Cellular Biochemistry

, Volume 452, Issue 1–2, pp 83–94 | Cite as

Silibinin ameliorates amylin-induced pancreatic β-cell apoptosis partly via upregulation of GLP-1R/PKA pathway

  • Jing Yang
  • Yue Sun
  • Fanxing Xu
  • Weiwei Liu
  • Yingsi Mai
  • Toshihiko Hayashi
  • Shunji Hattori
  • Yuko Ushiki-Kaku
  • Satoshi Onodera
  • Shin-ichi Tashiro
  • Takashi IkejimaEmail author
Article
  • 112 Downloads

Abstract

The objective was to investigate the mechanism of the protective effect of silibinin on amylin/Aβ1−42-induced INS-1 cell apoptosis, with special reference to the roles of glucagon-like peptide-1 receptor (GLP-1R) and protein kinase A (PKA). The effects of silibinin on apoptosis, insulin secretion, GLP-1R, and PKA expression in the INS-1 cells treated with amylin/Aβ1−42 were examined. INS-1 cells exposed to amylin showed increased TUNEL-positive ratio, reduced expression of GLP-1R and PKA. GLP-1R antagonists or PKA inhibitor enhanced the expression of apoptosis-associated proteins and TUNEL-positive ratio. Silibinin exerted antiapoptotic effect on and upregulation of GLP-1R and PKA. However, Aβ1−42-induced INS-1 cell apoptosis, GLP-1R, and PKA expressions were not changed. Our results indicate that down-regulation of GLP-1R and PKA contributes to INS-1 cell apoptosis induced with amylin. Silibinin protects INS-1 cells from amylin-induced apoptosis through activation of GLP-1R/PKA signaling. Silibinin’s inhibition of the toxic effects of Aβ1−42 is independent of GLP-1R/PKA pathway.

Keywords

Silibinin INS-1 cells GLP-1R PKA Apoptosis 

Notes

Acknowledgements

This study was supported by Innovation and Entrepreneurship Training Program of Shenyang Pharmaceutical University (201710163000006), Foundation of Liaoning Education Committee (51120427), and Doctoral Starting up Foundation of Liaoning Science and Technology Department (51120390).

Compliance with ethical standards

Conflict of interest

The authors have declared that there is no conflict of interest.

References

  1. 1.
    Donath MY et al (2005) Mechanisms of beta-cell death in type 2 diabetes. Diabetes 54(Suppl 2):S108–S113Google Scholar
  2. 2.
    Sahyoun NR et al (2008) Dietary diabete glycemic index and glycemic load and the risk of type 2 diabetes in older adults. Am J Clin Nutr 87:126–131Google Scholar
  3. 3.
    Janikiewicz J, Hanzelka K, Kozinski K, Kolczynska K, Dobrzyn A (2015) Islet beta-cell failure in type 2 diabetes—within the network of toxic lipids. Biochem Biophys Res Commun 460:491–496.  https://doi.org/10.1016/j.bbrc.2015.03.153 Google Scholar
  4. 4.
    Haataja L, Gurlo T, Huang CJ, Butler PC (2008) Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev 29:303–316.  https://doi.org/10.1210/er.2007-0037 Google Scholar
  5. 5.
    Westermark P, Andersson A, Westermark GT (2011) Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev 91:795–826.  https://doi.org/10.1152/physrev.00042.2009 Google Scholar
  6. 6.
    Park YJ et al (2013) The glucagon-like peptide-1 receptor agonist exenatide restores impaired pro-islet amyloid polypeptide processing in cultured human islets: implications in type 2 diabetes and islet transplantation. Diabetologia 56:508–519.  https://doi.org/10.1007/s00125-012-2802-z Google Scholar
  7. 7.
    Jurgens CA et al (2011) beta-cell loss and beta-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol 178:2632–2640.  https://doi.org/10.1016/j.ajpath.2011.02.036 Google Scholar
  8. 8.
    Velander P, Wu L, Ray WK, Helm RF, Xu B (2016) Amylin amyloid inhibition by flavonoid baicalein: key roles of its vicinal dihydroxyl groups of the catechol moiety. Biochemistry 55:4255–4258.  https://doi.org/10.1021/acs.biochem.6b00578 Google Scholar
  9. 9.
    Ma L, Li X, Wang Y, Zheng W, Chen T (2014) Cu(II) inhibits hIAPP fibrillation and promotes hIAPP-induced beta cell apoptosis through induction of ROS-mediated mitochondrial dysfunction. J Inorg Biochem 140:143–152.  https://doi.org/10.1016/j.jinorgbio.2014.07.002 Google Scholar
  10. 10.
    Zhang XX, Pan YH, Huang YM, Zhao HL (2016) Neuroendocrine hormone amylin in diabetes. World J Diabetes 7:189–197.  https://doi.org/10.4239/wjd.v7.i9.189 Google Scholar
  11. 11.
    Verma N et al (2016) Intraneuronal amylin deposition, peroxidative membrane injury and increased IL-1beta synthesis in brains of Alzheimer’s disease patients with type-2 diabetes and in diabetic HIP rats. J Alzheimer Dis 53:259–272.  https://doi.org/10.3233/JAD-160047 Google Scholar
  12. 12.
    Mietlicki-Baase EG (2016) Amylin-mediated control of glycemia, energy balance, and cognition. Physiol Behav 162:130–140.  https://doi.org/10.1016/j.physbeh.2016.02.034 Google Scholar
  13. 13.
    Fu W, Patel A, Jhamandas JH (2013) Amylin receptor: a common pathophysiological target in Alzheimer’s disease and diabetes mellitus. Front Aging Neurosci 5:42.  https://doi.org/10.3389/fnagi.2013.00042 Google Scholar
  14. 14.
    Lutz TA, Meyer U (2015) Amylin at the interface between metabolic and neurodegenerative disorders. Front Neurosci 9:216.  https://doi.org/10.3389/fnins.2015.00216 Google Scholar
  15. 15.
    Akesson B, Panagiotidis G, Westermark P, Lundquist I (2003) Islet amyloid polypeptide inhibits glucagon release and exerts a dual action on insulin release from isolated islets. Regul Pept 111:55–60Google Scholar
  16. 16.
    Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131–2157.  https://doi.org/10.1053/j.gastro.2007.03.054 Google Scholar
  17. 17.
    Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409–1439.  https://doi.org/10.1152/physrev.00034.2006 Google Scholar
  18. 18.
    Salehi M, Aulinger BA, D’Alessio DA (2008) Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev 29:367–379.  https://doi.org/10.1210/er.2007-0031 Google Scholar
  19. 19.
    Vahl TP et al (2007) Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148:4965–4973.  https://doi.org/10.1210/en.2006-0153 Google Scholar
  20. 20.
    Duca FA et al (2015) Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nat Med 21:506–511.  https://doi.org/10.1038/nm.3787 Google Scholar
  21. 21.
    Chepurny OG et al (2009) Enhanced Rap1 activation and insulin secretagogue properties of an acetoxymethyl ester of an Epac-selective cyclic AMP analog in rat INS-1 cells: studies with 8-pCPT-2′-O-Me-cAMP-AM. J Biol Chem 284:10728–10736.  https://doi.org/10.1074/jbc.M900166200 Google Scholar
  22. 22.
    Hashiguchi H et al (2006) Cyclic AMP/cAMP-GEF pathway amplifies insulin exocytosis induced by Ca2+ and ATP in rat islet beta-cells. Diabetes/Metab Res Rev 22:64–71.  https://doi.org/10.1002/dmrr.580 Google Scholar
  23. 23.
    Meloni AR, DeYoung MB, Lowe C, Parkes DG (2013) GLP-1 receptor activated insulin secretion from pancreatic beta-cells: mechanism and glucose dependence. Diabetes Obes Metab 15:15–27.  https://doi.org/10.1111/j.1463-1326.2012.01663.x Google Scholar
  24. 24.
    Lockshin RA, Zakeri Z (2004) Apoptosis, autophagy, and more. Int J Biochem Cell Biol 36:2405–2419.  https://doi.org/10.1016/j.biocel.2004.04.011 Google Scholar
  25. 25.
    Cohen GM (1997) Caspases: the executioners of apoptosis. The Biochem J 326(Pt 1):1–16Google Scholar
  26. 26.
    Liu W et al (2013) Interference of silibinin with IGF-1R signalling pathways protects human epidermoid carcinoma A431 cells from UVB-induced apoptosis. Biochem Biophys Res Commun 432:314–319.  https://doi.org/10.1016/j.bbrc.2013.01.109 Google Scholar
  27. 27.
    Green D, Kroemer G (1998) The central executioners of apoptosis: caspases or mitochondria? Trends Cell Biol 8:267–271Google Scholar
  28. 28.
    Huang CF et al (2018) Low-dose tributyltin exposure induces an oxidative stress-triggered JNK-related pancreatic beta-cell apoptosis and a reversible hypoinsulinemic hyperglycemia in mice. Sci Rep 8:5734.  https://doi.org/10.1038/s41598-018-24076-w Google Scholar
  29. 29.
    Yang J et al (2018) Involvement of estrogen receptors in silibinin protection of pancreatic beta-cells from TNFalpha- or IL-1beta-induced cytotoxicity. Biomed Pharmacother 102:344–353.  https://doi.org/10.1016/j.biopha.2018.01.128 Google Scholar
  30. 30.
    Dehmlow C, Erhard J, de Groot H (1996) Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 23:749–754.  https://doi.org/10.1053/jhep.1996.v23.pm0008666328 Google Scholar
  31. 31.
    Duan W et al (2010) Silibinin induced autophagic and apoptotic cell death in HT1080 cells through a reactive oxygen species pathway. J Pharmacol Sci 113:48–56Google Scholar
  32. 32.
    Wang T et al (2017) The protective effects of silibinin in the treatment of streptozotocin-induced diabetic osteoporosis in rats. Biomed Pharmacother 89:681–688.  https://doi.org/10.1016/j.biopha.2017.02.018 Google Scholar
  33. 33.
    Wang Q et al (2012) In vivo recovery effect of silibinin treatment on streptozotocin-induced diabetic mice is associated with the modulations of Sirt-1 expression and autophagy in pancreatic beta-cell. J Asian Nat Prod Res 14:413–423.  https://doi.org/10.1080/10286020.2012.657180 Google Scholar
  34. 34.
    Song X et al (2017) Silibinin ameliorates anxiety/depression-like behaviors in amyloid beta-treated rats by upregulating BDNF/TrkB pathway and attenuating autophagy in hippocampus. Physiol Behav 179:487–493.  https://doi.org/10.1016/j.physbeh.2017.07.023 Google Scholar
  35. 35.
    Song X et al (2018) Estrogen receptors are involved in the neuroprotective effect of Silibinin in abeta1–42-treated rats. Neurochem Res.  https://doi.org/10.1007/s11064-018-2481-3 Google Scholar
  36. 36.
    Song X et al (2017) Silibinin ameliorates Abeta25-35-induced memory deficits in rats by modulating autophagy and attenuating neuroinflammation as well as oxidative stress. Neurochem Res 42:1073–1083.  https://doi.org/10.1007/s11064-016-2141-4 Google Scholar
  37. 37.
    Waterborg JH, Matthews HR (1984) The lowry method for protein quantitation. Methods Mol Biol 1:1–3.  https://doi.org/10.1385/0-89603-062-8:1 Google Scholar
  38. 38.
    Yu OH, Yin H, Azoulay L (2015) The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death. Can J Diabetes 39:383–389.  https://doi.org/10.1016/j.jcjd.2015.02.002 Google Scholar
  39. 39.
    Foretz M, Viollet B (2014) New promises for metformin: advances in the understanding of its mechanisms of action. Med Sci 30:82–92.  https://doi.org/10.1051/medsci/20143001018 Google Scholar
  40. 40.
    Gilman S et al (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553–1562.  https://doi.org/10.1212/01.WNL.0000159740.16984.3C Google Scholar
  41. 41.
    Sakono M, Zako T (2010) Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J 277:1348–1358.  https://doi.org/10.1111/j.1742-4658.2010.07568.x Google Scholar
  42. 42.
    Bharadwaj P et al (2017) The link between type 2 diabetes and neurodegeneration: roles for amyloid-beta, amylin, and tau proteins. J Alzheimer Dis.  https://doi.org/10.3233/JAD-161192 Google Scholar
  43. 43.
    Miklossy J et al (2010) Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging 31:1503–1515.  https://doi.org/10.1016/j.neurobiolaging.2008.08.019 Google Scholar
  44. 44.
    Cai HY et al (2014) Lixisenatide rescues spatial memory and synaptic plasticity from amyloid beta protein-induced impairments in rats. Neuroscience 277:6–13.  https://doi.org/10.1016/j.neuroscience.2014.02.022 Google Scholar
  45. 45.
    Yin F, Zhang Y, Guo L, Kong S, Liu J (2012) Geniposide regulates insulin-degrading enzyme expression to inhibit the cytotoxicity of Abeta1–42 in cortical neurons. CNS Neurol Disord Drug Targets 11:1045–1051Google Scholar
  46. 46.
    Perry T, Greig NH (2005) Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer’s disease. Curr Alzheimer Res 2:377–385Google Scholar
  47. 47.
    Zhang Y, Xia Z, Liu J, Yin F (2015) Cell signaling mechanisms by which geniposide regulates insulin-degrading enzyme expression in primary cortical neurons. CNS Neurol Disord Drug Targets 14:370–377Google Scholar
  48. 48.
    Gupta A, Bisht B, Dey CS (2011) Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s-like changes. Neuropharmacology 60:910–920.  https://doi.org/10.1016/j.neuropharm.2011.01.033 Google Scholar
  49. 49.
    Koenig AM et al (2017) Effects of the insulin sensitizer metformin in alzheimer disease: pilot data from a randomized placebo-controlled crossover study. Alzheimer Dis Assoc Disord 31:107–113.  https://doi.org/10.1097/WAD.0000000000000202 Google Scholar
  50. 50.
    Chen B, Teng Y, Zhang X, Lv X, Yin Y (2016) Metformin alleviated abeta-induced apoptosis via the suppression of JNK MAPK signaling pathway in cultured hippocampal neurons. BioMed Res Int.  https://doi.org/10.1155/2016/1421430 (2016)Google Scholar
  51. 51.
    DiTacchio KA, Heinemann SF, Dziewczapolski G (2015) Metformin treatment alters memory function in a mouse model of Alzheimer’s disease. J Alzheimer Dis 44:43–48.  https://doi.org/10.3233/JAD-141332 Google Scholar
  52. 52.
    Ahmad W, Ebert PR (2017) Metformin attenuates abeta pathology mediated through levamisole sensitive nicotinic acetylcholine receptors in a C. elegans model of Alzheimer’s disease. Mol Neurobiol 54:5427–5439.  https://doi.org/10.1007/s12035-016-0085-y Google Scholar
  53. 53.
    Yusta B et al (2006) GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 4:391–406.  https://doi.org/10.1016/j.cmet.2006.10.001 Google Scholar
  54. 54.
    Seeliger J, Weise K, Opitz N, Winter R (2012) The effect of Abeta on IAPP aggregation in the presence of an isolated beta-cell membrane. J\ Mol Biol 421:348–363.  https://doi.org/10.1016/j.jmb.2012.01.048 Google Scholar
  55. 55.
    Moreno-Gonzalez I et al (2017) Molecular interaction between type 2 diabetes and Alzheimer’s disease through cross-seeding of protein misfolding. Mol Psychiatry.  https://doi.org/10.1038/mp.2016.230 Google Scholar
  56. 56.
    Gotz J, Lim YA, Eckert A (2013) Lessons from two prevalent amyloidoses-what amylin and Abeta have in common. Front Aging Neurosci 5:38.  https://doi.org/10.3389/fnagi.2013.00038 Google Scholar
  57. 57.
    Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2002) Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23:599–622.  https://doi.org/10.1210/er.2001-0039 Google Scholar
  58. 58.
    Butler AE et al (2004) Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. Diabetes 53:1509–1516Google Scholar
  59. 59.
    Kapurniotu A (2001) Amyloidogenicity and cytotoxicity of islet amyloid polypeptide. Biopolymers 60:438–459Google Scholar
  60. 60.
    Arosio P, Vendruscolo M, Dobson CM, Knowles TP (2014) Chemical kinetics for drug discovery to combat protein aggregation diseases. Trends Pharmacol Sci 35:127–135.  https://doi.org/10.1016/j.tips.2013.12.005 Google Scholar
  61. 61.
    Eisele YS et al (2015) Targeting protein aggregation for the treatment of degenerative diseases. Nat Rev Drug Discov 14:759–780.  https://doi.org/10.1038/nrd4593 Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Jing Yang
    • 1
  • Yue Sun
    • 1
  • Fanxing Xu
    • 1
  • Weiwei Liu
    • 1
  • Yingsi Mai
    • 1
  • Toshihiko Hayashi
    • 1
    • 2
  • Shunji Hattori
    • 3
  • Yuko Ushiki-Kaku
    • 3
  • Satoshi Onodera
    • 4
  • Shin-ichi Tashiro
    • 5
  • Takashi Ikejima
    • 1
    Email author
  1. 1.Wuya College of InnovationShenyang Pharmaceutical UniversityShenyangPeople’s Republic of China
  2. 2.Department of Chemistry and Life Science, School of Advanced EngineeringKogakuin UniversityHachiojiJapan
  3. 3.Nippi Research Institute of BiomatrixTorideJapan
  4. 4.Department of Clinical and Biomedical SciencesShowa Pharmaceutical UniversityTokyoJapan
  5. 5.Department of Medical Education and Primary CareKyoto Prefectural University of MedicineKyotoJapan

Personalised recommendations